Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Short Interest Down 38.8% in February

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) saw a significant drop in short interest during the month of February. As of February 13th, there was short interest totaling 877 shares, a drop of 38.8% from the January 29th total of 1,434 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 50,875 shares, the days-to-cover ratio is presently 0.0 days. Based on an average daily volume of 50,875 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the shares of the company are sold short.

Institutional Investors Weigh In On Barinthus Biotherapeutics

A hedge fund recently raised its stake in Barinthus Biotherapeutics stock. Renaissance Technologies LLC grew its holdings in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 115.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 143,100 shares of the company’s stock after buying an additional 76,800 shares during the quarter. Renaissance Technologies LLC owned 0.35% of Barinthus Biotherapeutics worth $100,000 as of its most recent filing with the SEC. 25.20% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on BRNS. HC Wainwright increased their target price on Barinthus Biotherapeutics from $3.00 to $4.00 and gave the company a “buy” rating in a research note on Monday, November 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Barinthus Biotherapeutics in a research report on Monday, December 22nd. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $4.00.

Barinthus Biotherapeutics Stock Up 0.2%

Barinthus Biotherapeutics stock opened at $0.58 on Friday. The business has a 50 day moving average price of $0.69 and a two-hundred day moving average price of $0.95. Barinthus Biotherapeutics has a 12 month low of $0.56 and a 12 month high of $2.92. The stock has a market cap of $23.85 million, a price-to-earnings ratio of -0.31 and a beta of -0.66.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.